As 2022 comes to a close, we review Big Molecule Watch’s top five biosimilar regulatory developments of the year...more
1/3/2023
/ America Invents Act ,
Biden Administration ,
Biosimilars ,
China ,
Drug Pricing ,
EU ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Governor Newsom ,
Interchangeability ,
Life Sciences ,
Orange Book ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Purple Book ,
USPTO
On December 24th, 2021, Innovent Biologics announced that China’s National Medical Products Administration had accepted its Supplemental New Drug Application (sNDA) for TYVYT®, a sintilimab plus bevacizumab biosimilar...more